Comienzos
keyboard_arrow_right
keyboard_arrow_right
Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail.
Nutrition

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail.

We believe ProLindac is usually brand-new DACH platinum chemotherapy in continued clinical development at this stage. Access’ Asian companions continue to prepare regulatory and other filings in South Korea and China to commence additional combination clinical studies with ProLindac. These research are expected to supply clinical data for additional indications for ProLindac beyond past due stage ovarian cancer. Additional indications under consideration include hepatocellular carcinoma, pancreatic, endometrial and others.. Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, starts combination study ACCESS PHARMACEUTICALS, INC. , today announced that it has finished enrollment and evaluation of the last additional cohort of patients in the ongoing medical study of ProLindac as a monotherapy in ovarian cancer patients who’ve received at least two prior platinum centered treatment regimens.The exhibit has been presented with the 2011 American Roentgen Ray Society’s annual achieving April 30 in Chicago. The exhibit was a collaborative effort between the Division of Radiology at Tripler Army INFIRMARY in Honolulu, HI, and the Joint POW/MIA Accounting Order/Central Identification Laboratory, at the Joint Bottom Pearl Harbor-Hickam, Hawaii.

AMD associated with impaired lysosomal autophagy, study finds A new research published in the prestigious PLoS One journal adjustments our understanding of the pathogenesis of age-related macular degeneration . The researchers found that degenerative adjustments and loss of vision are due to impaired function of the lysosomal clean-up system, or autophagy, in the fundus of the eye.